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(mCRC) was not recommended in the UK (until June 2009), but accepted under a 
price volume agreement scheme with prior authorization in Italy, and without restric-
tion in France and Germany. These products are funded on top of DRG costs in 
France, but not in other countries. We reviewed how such differences might affect 
usage of TRZ and CTX in France, Germany, Italy and UK. METHODS: Data on 
drug utilization from June 2006 to July 2009 were extracted from the Synovate Oncol-
ogy Monitor, an ongoing database tracking prescribing of anti-cancer therapies. 
Sample sizes varied between countries and indications, from 1700 to 6200 patients. 
RESULTS: Proportions of patients receiving TRZ from July 08 to June 09 ranged 
from 9% (UK) to 16% (Italy) in early BC, 12% (Italy) to 19% (France) in ﬁrst-line 
advanced BC and 10% (France) to 34% (Italy) in second-line (irrespective of HER2 
screening). For CTX, utilization rates ranged from 0% (UK) to 13% (France) in ﬁrst-
line and 2% (UK) to 19% (Italy) in second-line. Utilization of TRZ increased over 
time in early stage BC. Utilization of CTX was stable in France, increased in Germany 
and decreased in Italy. Dosages and patient proﬁles were comparable across countries. 
CONCLUSIONS: Funding on top of DRG does not appear to increase drug uptake. 
Health technology assessment conclusions inﬂuence utilization strongly. When access 
is granted, administrative constraints may reduce ﬁrst-line utilization to the beneﬁt of 
second-line. This should be considered when decisions are made about access to 
innovative medicine.
HT3
MULTICRITERIA DECISION ANALYSIS (MCDA) FOR DRUG COVERAGE 
DECISION BY A PUBLIC HEALTH PLAN: CASE STUDY OF TRAMADOL 
FOR CHRONIC NON-CANCER PAIN (CNCP) IN CANADA
Tony M1, Goetghebeur M1, Wagner M1, Khoury H1, Rindress D1, Oh P2
1BioMedCom Consultants Inc., Dorval, QC, Canada, 2University of Toronto, Toronto, 
ON, Canada
OBJECTIVES: To ﬁeld-test a decision support framework (EVIDEM) and explore its 
utility to a drug advisory committee using tramadol for chronic non-cancer pain 
(CNCP) as a case study. METHODS: The EVIDEM framework includes a multicri-
teria decision analyses matrix (MCDA) composed of 15 quantiﬁable components of 
decision including six domains (disease impact, context of intervention, intervention 
outcomes, type of beneﬁt, economics and quality of evidence) and a qualitative tool 
including six components of decision regarding ethical considerations, system capacity 
and political/historical context. A synthesized health technology assessment (HTA) 
report tailored to investigate each component of decision was developed for tramadol 
for CNCP. MCDA weights and scores, and qualitative considerations were provided 
by each committee member to evaluate tramadol from a public health plan perspective. 
RESULTS: The committee estimated the value of tramadol for CNCP at 44% (min: 
36%, max: 61%) of maximum value on the MCDA scale. Main contributors to the 
MCDA value estimate were size of population affected by disease (15% of total), 
disease severity (11%) and impact on adverse event expenditures (8%). Limited 
improvement in efﬁcacy, safety and patient reported outcomes were not signiﬁcant 
contributors to MCDA value. For a majority of committee members, ethical consid-
erations on utility, efﬁciency and fairness had respectively a positive, neutral and 
negative impact on the value of tramadol. CONCLUSIONS: By systematizing consid-
eration of all components of decision and underlying evidence, the framework allows 
consistent approach to evaluating health care interventions. Further testing and valida-
tion is needed to advance MCDA approaches in health care decisionmaking.
HT4
PRAGMATIC CLINICAL TRIALS FOR DRUG APPROVAL: IS IT REALISTIC?
Mohr P1, Sonnad S2, Mullins CD3, Whicher D1, Goldsack J2, Tunis SR1
1Center for Medical Technology Policy, Baltimore, MD, USA, 2University of Pennsylvania, 
Philadelphia, PA, USA, 3University of Maryland School of Pharmacy, Baltimore, MD, USA
BACKGROUND: Patients, clinicians, payers and policymakers increasingly are inter-
ested in understanding comparative “real world” effectiveness of pharmaceutical 
products, often noting that traditional clinical trials performed for regulatory approval 
may not address important questions about the full range of beneﬁts and harms of 
new drugs used in typical clinical settings. While more pragmatic designs are used for 
post-marketing studies, to date, no group formally has considered their utility and 
feasibility for regulatory approval trials. METHODS: In 2009, the Center for Medical 
Technology Policy convened an expert stakeholder working group to characterize 
recurring gaps in evidence that generally are not addressed in regulatory trials, explore 
the reasons for those shortcomings, and generate ideas for improving methods to make 
these trials more informative for patient and physician choices and reimbursement and 
coverage decisions. The working group included representatives from pharmaceutical 
companies, regulatory bodies, private and public payers, academics, consumers, and 
technology assessment organizations. Using discussions from this meeting and contin-
ued engagement of the working group over time, we developed a conceptual, meth-
odological and policy framework to improve the design and implementation of 
pragmatic regulatory trials. RESULTS: There emerged greater than anticipated con-
sensus among the regulators and payers participating in the working group that some 
pragmatic features are desirable and feasible to include in regulatory trials. The 
working group developed eight basic principles for making regulatory trials more 
pragmatic, covering the engagement of post-regulatory decision makers early in the 
design process to methods for designing more efﬁcient trials. CONCLUSIONS: The 
optimal approach to pragmatic trials may not involve incorporating all possible 
pragmatic features, as are typically associated with large, simple trials. Some domains 
of pragmatism are more important to payers than others and any incremental move-
ment toward more pragmatic designs may be not only highly valuable, but feasible.
PODIUM SESSION I: RESEARCH ON PRO METHODS  
(INCLUDING UTILITIES)
PR1
INCORPORATING TARIFF-LEVEL UNCERTAINTY AROUND ESTIMATES 
FROM THE CATALOGUE OF EQ-5D SCORES
Sullivan P1, Ghushchyan VH2, Slejko JF2
1Regis University School of Pharmacy, Denver, CO, USA, 2University of Colorado Denver, 
Aurora, CO, USA
OBJECTIVES: Analysts typically take as “ﬁxed” the underlying tariff scoring function 
of a given utility instrument when conducting probabilistic sensitivity analysis, ignor-
ing an important source of uncertainty. An “off-the-shelf” catalogue of EQ-5D scores 
from a nationally representative U.S. population has recently been published. The 
current study aims to incorporate the uncertainty in the underlying U.S. EQ-5D tariff 
function by estimating conﬁdence intervals around estimates from the catalogue. 
METHODS: The Medical Expenditure Panel Survey (MEPS), a general population 
survey in the U.S., was pooled (2000, 2001, 2002 and 2003) to create a sample of 
79,524 adults with valid EQ-5D responses. Chronic conditions were classiﬁed by 
ICD-9 codes and Clinical Classiﬁcation Category (CCC) codes. Censored least abso-
lute deviations (CLAD) regression methods were used to estimate the marginal disutil-
ity of each condition controlling for age, comorbidity, gender, race, ethnicity, income 
and education. US tariffs for the EQ-5D (Shaw) were applied to questionnaire 
responses. However, instead of taking the US EQ-5D tariff as a “ﬁxed” function of 
the questionnaire responses, 500 bootstraps were conducted drawing from a distribu-
tion of possible EQ-5D tariffs based on the standard errors from the original scoring 
estimation. RESULTS: A catalogue of marginal disutility (EQ-5D) scores for each 
chronic ICD-9 and CCC code were estimated 500 times based on the distribution of 
possible EQ-5D tariffs. The 95% range of these potential marginal disutilities is 
presented and compared. CONCLUSIONS: Scores and marginal disutilities for a wide 
variety of chronic ICD-9 and CCC codes can be used to estimate QALYs in cost-
effectiveness analyses. This research provides a range of values around each marginal 
disutility in the catalogue of “off-the-shelf” EQ-5D scores. Uncertainty in the underly-
ing US EQ-5D estimation tariff is incorporated in these ranges to encourage better 
understanding of the inherent uncertainty in EQ-5D estimates and to facilitate future 
probabilistic sensitivity analyses.
PR2
EVALUATING THE MEASUREMENT PROPERTIES OF AN AUGMENTED 
EQ-5D WITH THE INCLUSION OF TWO SINGLE QUALITY-OF-LIFE 
(QOL) INDICATORS USING THE MEDICAL EXPENDITURE PANEL 
SURVEY (MEPS)
Gu NY1, Bond TG2, Craig BM3
1Pharmerit North America, LLC, Bethesda, MD, USA, 2James Cook University, Townsville, 
QLD, Australia, 3Mofﬁtt Cancer Center, Tampa, FL, USA
OBJECTIVES: To evaluate the measurement properties of the EQ-5D proﬁle aug-
mented with its 0–100 mm visual analogue scale (VAS) and a 5-point summary self-
rating of health (SRH). METHODS: We used data from 4,001 adults from the 2003 
MEPS who had ≥1 of 7 most prevalent chronic conditions and completed the EQ-5D, 
VAS, and SRH. The original 101 VAS categories were collapsed into a 9-category 
item with sufﬁcient responses in each category. Five SRH categories included “excel-
lent”, “very good”, “good”, “fair” and “poor”. The Rasch rating scale and partial 
credit models were used to calibrate the EQ-5D and the single items, respectively. 
Calibrations were conducted using 4 different combinations: EQ-5D alone; EQ-
5D+SRH; EQ-5D+VAS, and EQ-5D+SRH+VAS. Model goodness-of-ﬁt was assessed 
in each disease group using INFIT mean squares (≤1.40). Principal Component Analy-
sis of Rasch Residuals was used to conﬁrm dimensionality examining the proportion 
of total variance explained by Rasch scale, person measures and item measures, 
respectively. RESULTS: Respondents were predominantly white, female, middle aged 
and suffered most commonly from hypertension (32%), diabetes (17%) and depres-
sion (15%). EQ-5D item “anxiety/depression” consistently showed misﬁt to the model 
across 7 conditions when EQ-5D was evaluated alone. The inclusion of VAS and/or 
SRH not only improved model ﬁt, but also increased overall variances explained, and 
improved overall distribution of persons and items along the latent health trait. Speciﬁ-
cally, when both items were included, 4 groups showed good model ﬁt (mean squares 
≤1.40). Consistently across all groups, VAS captured more person measures while 
SRH captured more item measures. CONCLUSIONS: The EQ-5D’s measurement 
qualities are enhanced by the inclusion of VAS/SRH, which captures integral aspect 
of self-valuations on health that are possibly overlooked by the EQ-5D. The EQ-
5D+VAS+SRH may serve as a suitable measurement framework for deriving popula-
tion preference-weights. Consequently, a new valuation algorithm is called for.
PR3
NATIONAL CULTURE AND EQ-5D VALUE SETS
Bailey H1, Kind P2
1The University of the West Indies, Maracas Valley, Trinidad and Tobago, 2University of 
York, York, UK
Background Despite the growing importance of the EQ-5D descriptive system as a 
basis for the valuation of QALYs in cost-utility analysis, for most countries there are 
no EQ-5D social value sets. Researchers and policy makers wishing to use the EQ-5D 
descriptive system in a country for which there is no value set are advised to use one 
from a nearby or ‘similar’ population. Factors other than geographic proximity can 
affect the relative values of EQ-5D states. Objective This study explores the links 
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between national culture and EQ-5D value sets. Method Rank correlation analysis is 
used to explore relationships between the relative values of a set of EQ-5D states and 
dimensions of national culture. The latter are taken from Hofstede’s framework which 
operationalizes national culture in 5 dimensions. The analysis is carried out using data 
from the countries for which EQ-5D value sets and scores on Hofstede’s dimensions 
of culture both exist: Argentina, Denmark, Germany, Japan, Korea, The Netherlands, 
Poland, Spain, UK, USA. Results Some relationships among the EQ-5D dimensions 
and culture are observed. Eg. the culture dimension: Power-Distance correlates 
strongly with the EQ-5D dimension: Anxiety-Depression (Spearman’s Rho for Power-
Distance indices and TTO valuations of EQ-5D states 11112 and 11113 are 0.523 
and 0.815 respectively). Strong and moderate relationships are observed among other 
culture dimensions (Individualism, Masculinity, Uncertainty-Avoidance) and EQ-5D 
dimensions (Pain, Self-Care). Discussion Different cultures appear to value EQ-5D 
dimensions differently. The correlation patterns observed in this study are generally 
consistent with a priori expectations based on the nature of the dimensions of culture 
and the EQ-5D model. This analysis demonstrates the potential of national culture in 
providing insight into the drivers of the relative values of EQ-5D dimensions for dif-
ferent countries, and in informing decisions about which EQ-5D value sets to use in 
situations where one does not exist.
PR4
ARE HEALTH STATES “TIMELESS”? A TEST OF THE UTILITY 
INDEPENDENCE ASSUMPTION: COMPARING A REPEATED MEASURES 
DESIGN AND LATENT GROWTH MODELING
Franic D1, Gafni A2, Vandenberg R1
1University of Georgia, Athens, GA, USA, 2McMaster University, Hamilton, ON, Canada
OBJECTIVES Primary study objective was to test whether individuals’ responses to 
standard gamble (SG) questions do not depend on the duration of time spent in the 
health scenario presented (“timelessness”). Secondary objective of the study was to 
test the “timelessness” of VAS responses. METHODS Face-to-face interviews were 
conducted in a convenience sample of healthy volunteers (n = 59) aged 20 to 63. 
Individuals rated their preferences for three health states of varying post chemotherapy 
nausea and vomiting (PCNV) severity and current health, assuming six different time 
horizons. Repeated measures analysis of variance (RM-ANOVA) was conducted 
(SX6X4X2) to determine the affect of time (6 levels:3 days, 3 months, 1-, 5- and 
20- year(s) and rest of life), health state (4 levels: mild, moderate and severe PCNV 
and current health), and method (2 levels: SG and VAS) on preference. RESULTS 
Results were analyzed using RM-ANOVA and latent growth modeling (LGM). Both 
showed that preferences decreased over time for SG and VAS (p < 0.05). For the 
RM-ANOVA, all main effects and interaction terms were signiﬁcant (p < 0.05). LGM 
showed acceptable ﬁt and signiﬁcant slope parameters for all PCNV. The slopes were 
decreasing over time. Signiﬁcant latent variances for LGM showed that not all indi-
viduals change at the same rate over time (p < 0.05) CONCLUSIONS There is a clear 
advantage in the use of LGM over RM-ANOVA because LGM can evaluate group 
differences in addition to individual changes over time. For the majority of respondents 
the utility independence assumption for SG and VAS did not hold both at the group 
and the individual level. Similar to Bala et al (1999) and Franic et al (2003) the results 
of this study indicated preferences as measured by SG and VAS are not timeless. 
Regardless of the preference measure used: both SG and VAS yield higher preferences 
for shorter time horizons.
PODIUM SESSION I: RISK MANAGEMENT STUDIES
RM1
COMPARATIVE PERFORMANCE OF RISK ADJUSTMENT MEASURES IN A 
SAMPLE OF COMMERCIALLY-INSURED PATIENTS UNDER AGE 65—
TWO SIMPLE MEASURES OUTPERFORM CURRENT STANDARDS
Fowler R, Johnston SS
Thomson Reuters, Washington, DC, USA
OBJECTIVES: Numerous studies have compared risk adjustment measures (RAMs), 
yet none have done so across various outcomes in multiple acute and chronic condi-
tions in a single database with uniform programmatic operationalization. This study 
compares the performance of 7 RAMs and highlights practical programming consid-
erations for hands-on data analysts operationalizing RAMs. METHODS: Data were 
administrative claims from the 2006–2008 MarketScan® Commercial Database. 
Seven RAMs (2 Deyo-Charlson Comorbidity Index variations, Chronic Disease Score 
[CDS], 2 3-digit ICD-9-CM code count variations, number of unique National Drug 
Classiﬁcation [NDC] codes, and number of unique drug molecules) measured over a 
1-year baseline period were compared in 7 conditions (acute coronary syndrome, 
sample N = 14,951; rheumatoid arthritis [RA], N = 27,085; depression, N = 129,206; 
diabetes, N = 126,087; hypertension, N = 225,080; asthma, N = 56,172; ﬁbromyalgia, 
N = 52,365) on the basis of 3 outcomes (total health care cost, emergency room [ER] 
visits, inpatient admissions) measured over a 1-year follow-up period. Goodness-of-ﬁt 
statistics (chi-squared statistic for total health care costs and c-statistic for ER visits 
and inpatient admissions) were compared across age and sex-adjusted regression 
models for each individual RAM. RESULTS: A unique 3-digit ICD-9-CM code count 
that excluded ‘rule-out’ diagnoses consistently outperformed, i.e., had highest chi-
squared and c-statistics, every other RAM in every condition and outcome with the 
exception of the number of unique NDC codes, which performed the best for all 
outcomes in depression and ﬁbromyalgia patients. The number of unique NDC codes 
was generally the second-best performing RAM across all outcomes. The CDS per-
formed worst across every condition and outcome. CONCLUSIONS: Complex RAMs 
are subject to inconsistencies in their operationalization and application from a pro-
gramming perspective. Across multiple acute and chronic conditions, the two simplest 
and programmatically-transparent RAMs were the most predictive measures of total 
health care cost, ER visits, and inpatient admissions.
 RM2
IMPACT OF ADHERENCE WITH STATIN THERAPY ON 
HOSPITALIZATION RISK AND MORTALITY AMONG PATIENTS  
WITH DIABETES
Yang Y, Banahan BF, Pace PF
University of Mississippi, University, MS, USA
OBJECTIVES: The objective of this study was to evaluate the impact of adherence 
with statin therapy on diabetes-speciﬁc hospitalization and all-cause mortality among 
patients with diabetes enrolled in a state Medicaid program. METHODS: The authors 
conducted a retrospective cohort study of patients with diabetes who were continu-
ously enrolled in a state Medicaid program from January 2002 to December 2004. 
The date of the ﬁrst medication claim for statin during the ﬁrst six months of 2002 
was the index date. Adherence to statin was assessed within one year following the 
index date. Adherence was assessed using the proportion of days covered (PDC) and 
patients with a PDC of 0.8 or greater considered being adherent. The primary out-
comes of interest were diabetes-speciﬁc hospitalization and all-cause mortality during 
the follow-up period (end of adherence measurement to December 31, 2004). Multi-
variate regression analyses were performed to assess the impact of adherence with 
statin therapy on outcome measures. RESULTS: A total 10,839 patients were included 
in the study. Mean age 60.3 ± 10.0 years, 23.8% male, 76.2 female; 31.7% white, 
50.4% black. At 12 months after the index prescription, only 23.9% of patients were 
adherent with their prescribed statin therapy. During follow-up After controlling for 
age, gender, race, prior hospitalization, and Charlson comorbidity index, patients who 
were adherent to statin therapy were 48.7% (OR: 0.513; 95%CI: 0.421–0.624) less 
likely to have diabetes-speciﬁc hospital admissions in comparison to nonadherent 
patients. Adherence with statin therapy had no statistically signiﬁcant impact on all-
cause mortality (OR: 0.801; 95%CI: 0.454–1.412). CONCLUSIONS: Adherence 
with statin therapy was poor among patients with diabetes enrolled in a Medicaid 
program. Adherence with statin therapy was associated with signiﬁcantly less risk for 
diabetes-speciﬁc hospitalization. Greater efforts are needed to facilitate diabetes self-
management behaviors to improve patient outcomes.
RM3
RISK OF FALLS AND FRACTURES IN OLDER ADULTS USING 
ATIPSYCHOTIC AGENTS- A PROPENSITY-MATCHED RETROSPECTIVE 
COHORT STUDY
Mehta S, Aparasu RR, Chen H, Johnson M
University of Houston, Houston, TX, USA
OBJECTIVES: To examine the risk of falls/fractures associated with atypical antipsy-
chotic use compared to typical antipsychotic use in community dwelling older adults. 
METHODS: The population based retrospective cohort analysis based on propensity 
score matching was conducted using IMS LifeLink™ Health Plan claims data. Patients 
were included in the cohort if they met following criteria: ≥ 50 years of age, new users 
of atypical or conventional antipsychotics who began taking antipsychotics between 
July 2000 and December 2007, and continuously enrolled for six months before and 
at least six months after initiation of antipsychotic treatment. Patients taking atypical 
antipsychotics were matched with those using typical antipsychotics using propensity 
score greedy matching technique. Kaplan-Meier survival curves and Cox proportional 
hazard model stratiﬁed on matched pair was employed to examine risk of hospitaliza-
tion/emergency visit due to falls or femur fractures within one year. Duration of 
antipsychotic therapy and exposure to other psychotropic medications were controlled 
for in the ﬁnal model. RESULTS: A total of 11,160 older adults (5,580 atypical and 
5,580 typical users) were identiﬁed as new users of antipsychotics after matching. 
Within one year of follow up period, 456 patients (8.06 %) in atypical drug group 
had falls/femur fractures compared to 375 (6.72%) in typical antipsychotic group. No 
signiﬁcant difference was found between atypical users compared to typical agents 
with respect to risk of falls/fractures [Hazard Ration (HR) 1.01, 95% CI 0.83–1.22]. 
However, duration of therapy more than 90 days was signiﬁcantly (HR, 1.81, CI, 
1.35–2.43) associated with increased risk of falls/fractures compared to less than 30 
days. CONCLUSIONS: The study results show no signiﬁcant difference in the risk of 
falls/fractures between atypical and typical antipsychotic use among older adults. 
However, there is a need to be cautious while prescribing atypical and typical anti-
psychotics in older adults for longer periods of time.
RM4
CONFOUNDING EFFECT OF AGE IN THE ASSOCIATION OF 
CARDIOVASCULAR RISK AND DIETARY SUPPLEMENT USE  
AMONG US ADULTS
Yu S, Shaw JW, Crawford SY, Groo V
University of Illinois at Chicago, Chicago, IL, USA
OBJECTIVES: Dietary supplement (DS) use has been found to be associated with 
cardiovascular disease (CVD) risk. This study assessed whether age moderates or 
confounds the association between CVD risk and DS use. METHODS: Data were 
taken from the 1999–2004 waves of the National Health and Nutrition Examination 
Survey. Inferences were restricted to US population members ≥20 years of age as 
